Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Senhwa BiosciencesROCO:6492 -1.35%70 Gross Margin % is 16.67% as of Dec. 2025, which is 66% below its 10-year median of 49.55. GuruFocus rates ROCO:6492 with a GF Score™ of 70/100 and a GF Value™ of NT$46.74 (Fairly Valued). The stock has 2 warning signs investors should review. Among 732 Biotechnology companies, Senhwa Biosciences ranks worse than 61.2% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Senhwa Biosciences had a gross margin of 16.67% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Senhwa Biosciences Gross Margin % Related Terms
Senhwa Biosciences Gross Margin % Historical Data
* Premium members only.
The historical data trend for Senhwa Biosciences's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6492 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Senhwa Biosciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senhwa Biosciences Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Senhwa Biosciences's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Senhwa Biosciences's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Senhwa Biosciences (ROCO:6492) has a Gross Margin % of 16.67% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Senhwa Biosciences and its competitors. This is 66% below median its historical median of 49.55. Over the past decade, Senhwa Biosciences' Gross Margin % has ranged from 10.23 to 58.73. According to the industry distribution chart, Senhwa Biosciences ranks #448 out of 732 companies in the Biotechnology industry, placing it in the top 61.2%.
Is Senhwa Biosciences' Gross Margin % too high?
Senhwa Biosciences' current Gross Margin % of 16.67% is 66% below median its 10-year median of 49.55. Over the past 10 years, this metric has ranged from a low of 10.23 to a high of 58.73. The Biotechnology industry median Gross Margin % is 60.91. Senhwa Biosciences' value of 16.67% is 72.6% below this industry median. Based on the distribution chart, Senhwa Biosciences ranks #448 out of 732 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Senhwa Biosciences has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Senhwa Biosciences' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Senhwa Biosciences ranks #448 out of 732 companies for Gross Margin %. This places Senhwa Biosciences in the lower half of its industry. The industry median Gross Margin % is 60.91. Senhwa Biosciences' value of 16.67% is 72.6% below this benchmark. Historically, Senhwa Biosciences' own Gross Margin % has ranged from 10.23 to 58.73 over the past decade. While the company's 10-year median is 49.55 vs. the industry median of 60.91, Senhwa Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Senhwa Biosciences's current Gross Margin % of 16.67% is 72.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Senhwa Biosciences and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Senhwa Biosciences's current Gross Margin % is 16.67%, which is 66% below median its own 10-year median of 49.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senhwa Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Senhwa Biosciences (ROCO:6492) is currently considered Fairly Valued. The stock's GF Value™ is NT$46.74, compared to a current price of NT$43.70 — trading 6.5% below its estimated fair value. The current Gross Margin % is 16.67%, which is 66% below median its 10-year median of 49.55 and 72.6% below the Biotechnology industry median of 60.91. Senhwa Biosciences' overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Senhwa Biosciences (ROCO:6492), the current Gross Margin % is 16.67% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Senhwa Biosciences (ROCO:6492) Overvalued in 2026?
Based on GuruFocus' analysis, Senhwa Biosciences stock appears to be undervalued.
The current stock price of NT$43.70 is trading 6.5% below its estimated GF Value™ of NT$46.74.
GuruFocus considers Senhwa Biosciences to be Fairly Valued.
Key valuation signals for ROCO:6492:
Gross Margin %: 16.67% (66% below median its 10-year median of 49.55)
GF Value™: NT$46.74 vs. price of NT$43.70 (6.5% below fair value)
Industry Position: 72.6% below the Biotechnology median (#448 of 732)
No single metric tells the full story. See the ROCO:6492 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Senhwa Biosciences Inc is engaged in the development of new drugs and special pharmaceutical ingredients, focusing on human efficacy. The company's product pipeline includes Pidnarulex (CX-5461), being developed as a therapy for solid tumours, B-cell lymphoma, ovarian cancer, and other oncology indications; and Silmitasertib (CX-4945), being developed to counter neuroblastoma, medulloblastoma, basal cell carcinoma, and other indications. Geographically, the company generates all of its revenue from Taiwan.
70GF Score
Get the complete analysis for ROCO:6492
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6492 has been successfully added to your 
